Shareholders of RCI Hospitality Holdings, Inc. (RICK): Protect Your Rights Before November 20, 2025 – Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / November 14, 2025 / If you suffered a loss on your RCI Hospitality Holdings, Inc. (NASDAQ:RICK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rci-hospitality-holdings-inc-lawsuit-submission-form?prid=177362&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com […]

LEOTEK Showcases Intelligent Sustainable Infrastructure at the UN Climate Change Conference (COP30), Driving the Global Net-Zero Transition

LEOTEKparticipated in the United Nations Climate Change Conference (COP30), presenting its innovations at the Digital Innovation Pavilion organized by the Taiwan Climate Partnership within the Blue Zone.Ewing Liu, Chief of Staff and Vice President of Sales atLEOTEK's U.S. headquarters, delivered a keynote speech titled “Lighting the Net-Zero Path: Global Practices in Intelligent Sustainable Infrastructure,” sharing

Zimmer Biomet Receives U.S. FDA Clearance for Enhanced Version of ROSA® Knee Robotic Technology

ROSA® Knee with OptimiZe™ Offers Personalized Surgical Planning and Drives Confidence in Delivering Accurate and Reproducible Outcomes1 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ROSA® Knee with OptimiZe™,an enhanced version of its ROSA® Knee System that offers a

Specialty Alumina Market Size to Worth USD 11.12 Billion by 2034

Specialty Alumina Market Size to Worth USD 11.12 Billion by 2034 According to Towards Chemical and Materials Consulting, the global specialty alumina market size is calculated at USD 4.98 billion in 2025 and is expected to be worth around USD 11.12 billion by 2034, growing at a compound annual growth rate (CAGR) of 9.35% over

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation GlobeNewswire November 14, 2025 New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancers GVHD trial launching through non-dilutive funding from NIH- and philanthropic grants Launching Phase 2+

LM Funding America, Inc. Reports Third Quarter 2025 Financial Results

LM Funding America, Inc. Reports Third Quarter 2025 Financial Results GlobeNewswire November 14, 2025 – Acquired 11 MW site in Mississippi with 7.5 MW mining in September and 26 MW total power capacity– Raised net $21.3 million in August to build Bitcoin Treasury– Mining margin improved to 49.0% from 41.0% in Q2 2025– Executed private

Positive Assay Results and Upcoming Drilling at Pense Critical Metals Project

Positive Assay Results and Upcoming Drilling at Pense Critical Metals Project GlobeNewswire November 14, 2025 TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) — Sparton Resources Inc. (TSXV-SRI) (“Sparton” or the “Company”) is pleased to announce the receipt of encouraging assay results from surface samples collected earlier this year from the Verrier-Gagne zone, in Ontario. For additional

Brixton Metals Announces Non-Brokered Private Placement of up to $18 Million

Brixton Metals Announces Non-Brokered Private Placement of up to $18 Million Not for distribution to United States Newswire Services or for dissemination in the United States GlobeNewswire November 14, 2025 VANCOUVER, British Columbia, Nov. 14, 2025 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton“) is pleased to announce a

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer’s Disease

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease GlobeNewswire November 14, 2025 Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company's Alzheimer's Disease clinical trial results NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex”

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results GlobeNewswire November 14, 2025 BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025. On October 30, 2025, the

Scroll to Top